Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

63.22 +1.67 (+2.71%)
Streaming Delayed Price Updated: 11:55 AM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Tarsus Announces Proposed $100.0 Million Public Offering
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts ↗
 
Via Benzinga
News headline image
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Tarsus Pharmaceuticals's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Tarsus Pharmaceuticals - Mixed Projections ↗
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. 
Via Talk Markets
News headline image
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis 
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Recap: Tarsus Pharmaceuticals Q3 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview: Tarsus Pharmaceuticals ↗
 
Via Benzinga
News headline image
Expert Ratings for Tarsus Pharmaceuticals ↗
 
Via Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session
Via Investor Brand Network
News headline image
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported... 
Via Benzinga
Topics Stocks
News headline image
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
News headline image
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated 
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals ↗
 
Via Benzinga
News headline image
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results. 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging ↗
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected... 
Via Benzinga
Topics Stocks
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session
Via Investor Brand Network
News headline image
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Earnings Scheduled For November 9, 2023 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
News headline image
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.